Form 4: Myomo CMO Harry Kovelman Reports Stock Sale for Tax

Chief Medical Officer Harry Kovelman disposed of 7,635 shares of Myomo, Inc. to satisfy tax obligations related to RSU vesting.

Summary

• Harry Kovelman, Chief Medical Officer of Myomo, Inc., sold 7,635 shares of common stock.
• The transaction occurred on June 8, 2026, at a price of $1.33 per share.
• The sale was executed to cover tax withholding obligations resulting from the vesting of restricted stock units (RSUs) on June 5, 2026.
• Following this transaction, Kovelman retains beneficial ownership of 100,983 shares of Myomo common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative and required for tax compliance rather than a signal of management sentiment.

Positives

• The transaction was a mandatory tax-related sale rather than a discretionary divestment, indicating continued alignment with company equity.

Negatives

• The transaction represents a reduction in the officer's direct shareholding.

Risks

• Reliance on equity-based compensation may lead to periodic selling pressure for tax obligations.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that this is a routine administrative filing common in the medical technology sector, where executives frequently receive equity-based compensation that necessitates 'sell-to-cover' transactions for tax purposes.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation and tax compliance.
• The 'sell-to-cover' mechanism is a standard industry practice for managing tax liabilities associated with RSU vesting.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine tax-related sale.

Key Dates

Keywords

Myomo, MYO, Insider Trading, Form 4, Medical Technology, Equity Vesting